Daré Bioscience (DARE) investor relations material

Executive summary

• Focused exclusively on women's health for a decade, building a robust pipeline spanning contraception, menopause, sexual health, vaginal health, and infectious disease, targeting large, underserved populations.

• Employs a dual path strategy: commercializing proprietary formulations via 503B compounding, pursuing FDA approval, and advancing select solutions as branded consumer health products.

• Multiple near-term commercial launches expected, including DARE to PLAY Sildenafil Cream and DARE to RESTORE vaginal probiotics, with pre-fulfillment prescribing and telehealth access live nationwide as of February 2026.

• Pipeline includes DARE to RECLAIM (bioidentical hormone therapy ring), Ovaprene (non-hormonal contraceptive), and DARE-HPV (HPV therapeutic), all advancing toward commercialization or pivotal trials.

• Multiple programs supported by non-dilutive grant funding and strategic collaborations, minimizing shareholder dilution.

Financial highlights

• Ended 2025 with $24.7 million in cash and cash equivalents and $3.4 million in working capital.

• Generated $1.03 million in revenue for 2025, up from $9,784 in 2024.

• Raised $20.8 million in net proceeds from equity offerings and $27 million in royalty financings related to XACIATO.

• Received $13.6 million from Gates Foundation, $4.5 million from ARPA-H, and $1.3 million from NIH grants in 2025; over $75 million in non-dilutive funding awarded since 2018.

• SG&A expenses were $8.8 million (down from $9.2 million in 2024); R&D expenses reported at $5.5 million (down from $14.3 million), with actual R&D investment higher due to $13.9 million in contra-R&D grant funding.

Outlook and guidance

• Expect to begin recording product revenue from DARE to PLAY and Flora Sync LF5 in Q2 2026; DARE to RECLAIM revenue targeted for 2027.

• Ovaprene Phase III enrollment expected to complete in 2026, with topline data readout in 2027.

• DARE-HPV advancing to Phase II in 2026 with ARPA-H funding.

• Building toward a diversified, multi-product revenue profile across 2026 and 2027.

• Multiple near-term catalysts expected, including product launches, clinical trial milestones, and new revenue streams.